Hermetica Superfood Encyclopedia
The Short Answer
Virola spp. contain a diverse array of bioactive phenolics, stilbenes, polyketides, neolignans, and sesquiterpenes—including the ultra-potent antiproliferative stilbene (Z)-3,5,4′-trihydroxystilbene and cytotoxic polyketides—that act through antioxidant, antiproliferative, α-glucosidase inhibitory, and antiprotozoal mechanisms. The most quantitatively striking preclinical finding is (Z)-3,5,4′-trihydroxystilbene inhibiting Caco-2 colorectal cancer cell growth by 70% at just 0.25 µM, approximately 100-fold more potent than resveratrol at 25 µM in the same assay; however, all evidence remains in vitro or animal-based with no human clinical trials conducted to date.
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary KeywordNixi Pae Virola benefits
Nixi Pae — botanical close-up
Health Benefits
**Antiproliferative / Anticancer Potential**
The stilbene (Z)-3,5,4′-trihydroxystilbene isolated from Virola spp. inhibits Caco-2 colon cancer cell proliferation by 70% at 0.25 µM; polyketides from V. sebifera show selective cytotoxicity against OVCAR03 ovarian and NCI-ADR/RES multidrug-resistant cancer lines at IC₅₀ values of 2–4 µg/mL, suggesting activity against chemotherapy-resistant tumors.
**Gastric Ulcer Protection**: Stem bark hydroethanolic extracts of V
elongata, containing 14.6% phenolics including gallic acid, catechin, and rutin, demonstrate antiulcer activity in rodent gastric ulcer models, likely through mucosal barrier reinforcement and antioxidant-mediated reduction of oxidative mucosal injury.
**Antioxidant Activity**
Ferulic acid, identified as the dominant phenolic in V. venosa methanolic bark and leaf extracts alongside quercetin, kaempferol, and p-coumaric acid, functions as a potent radical scavenger; this antioxidant capacity may protect cells against oxidative stress-driven pathology.
**Antidiabetic / α-Glucosidase Inhibition**: Ferulic acid from V
venosa inhibits α-glucosidase, the intestinal enzyme responsible for dietary carbohydrate breakdown and postprandial glucose spikes, suggesting a potential role in glycemic management analogous to acarbose-class drugs.
**Antimalarial Activity**: Leaf essential oil of V
surinamensis, rich in the sesquiterpene nerolidol, achieves 100% inhibition of Plasmodium falciparum trophozoite-to-schizont development within 48 hours in vitro, indicating potent stage-specific antimalarial action.
**Antiprotozoal / Anti-Leishmania Effects**: The O
4′-neolignan 3,4,5-trimethoxy-8[3′,5′-dimethoxy-4′-propenylphenoxy]-phenylpropane from V. pavonis demonstrates activity against Leishmania donovani promastigotes at 100 µM in vitro, relevant to visceral leishmaniasis for which treatment options remain limited.
**Hallucinogenic / Psychoactive Ethnopharmacology**
Bark resins of several Virola species contain tryptamine alkaloids—most notably 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT)—used by upper Orinoco tribes in the preparation of the hallucinogenic snuff called Nixi Pae or yakee; these compounds act as serotonin 5-HT2A receptor agonists producing profound altered states of consciousness.
Origin & History
Natural habitat
Virola species are tropical trees of the family Myristicaceae native to the Amazon and Orinoco river basins of South America, spanning Brazil, Venezuela, Colombia, Peru, and Suriname. They thrive in humid lowland rainforest and flooded várzea ecosystems, typically growing as canopy or sub-canopy trees in nutrient-poor, waterlogged soils. Indigenous cultivation is absent; trees are harvested wild, with bark, leaves, seeds, and resinous exudate collected by Yanomami, Tukano, and upper Orinoco tribes for ceremonial and medicinal use.
“Virola species have been central to the ceremonial and healing traditions of numerous Amazonian indigenous groups—most notably the Yanomami of Venezuela and Brazil and tribes of the upper Orinoco basin—for whom the potent hallucinogenic resin-snuff (known variously as yakee, paricá, or Nixi Pae) is administered by shamans (hekura) to facilitate communication with spirit worlds and to diagnose and treat illness. Ethnobotanist Richard Evans Schultes documented Virola use extensively in the mid-twentieth century, identifying it alongside Anadenanthera as one of the two principal botanical sources of tryptamine-based snuffs in lowland South America, and chemical analyses in the 1970s confirmed 5-MeO-DMT and DMT as the primary psychoactive alkaloids in the bark resin. Preparation traditionally involves scraping the reddish inner bark, heating the exudate to concentrate the resin, drying it, and sometimes mixing it with plant ash and Justicia pectoralis leaves before insufflation through a long bone or reed tube. Beyond psychoactive use, the same bark and leaf preparations have served as treatments for stomach ailments, skin infections, and fevers across multiple tribal groups, consistent with the phytochemically characterized antiulcer and antimicrobial activities.”Traditional Medicine
Scientific Research
The totality of published evidence for Virola spp. consists exclusively of in vitro bioassays, phytochemical characterization studies, and rodent ulcer models—no randomized controlled trials, observational cohort studies, or pharmacokinetic studies in humans have been identified. A comprehensive 2021 phytochemical review synthesizes findings across multiple species including V. elongata, V. sebifera, V. venosa, V. pavonis, and V. surinamensis, providing quantified IC₅₀ and inhibition data from cell-line experiments but without sample size reporting or statistical methodology sufficient for evidence grading. The most compelling preclinical datum—100-fold superior potency of (Z)-3,5,4′-trihydroxystilbene versus resveratrol at Caco-2 cells—requires validation in animal tumor models and ultimately human trials before any clinical significance can be assigned. Ethnopharmacological documentation of the hallucinogenic resin use is robust across anthropological literature, but controlled psychopharmacological studies of Virola-derived tryptamines specifically (as opposed to synthetic DMT or ayahuasca composites) are extremely sparse.
Preparation & Dosage
Traditional preparation
**Traditional Hallucinogenic Snuff (Yakee/Nixi Pae)**
Dried and powdered inner bark resin of Virola theiodora or related species is prepared by Yanomami and upper Orinoco shamans; no standardized dose exists—insufflated amounts vary by ceremony and individual. This preparation is not reproducible or safe outside traditional indigenous contexts.
**Hydroethanolic Bark Extract (Research Grade)**
Used in phytochemical studies of V. elongata at concentrations yielding 14.6% total phenolics; no human dosing equivalent established.
**Dichloromethane Leaf Extract (Research Grade)**
Applied in cytotoxicity assays for V. sebifera polyketides at IC₅₀ 2–4 µg/mL against cancer cell lines; no translatable human dose.
**Methanolic Bark/Leaf Extract (Research Grade)**
Used for V. venosa phenolic profiling; ferulic acid concentration and effective human dose not established.
**Leaf Essential Oil (Research Grade)**
V. surinamensis oil analyzed by GC-MS; effective antimalarial concentration in vitro does not correspond to any established human inhalation or topical dose.
**No commercial supplement form exists**
Virola spp. are not available as standardized dietary supplements; no pharmacopoeial monograph, GMP specification, or recommended daily intake has been established by any regulatory body.
Nutritional Profile
Virola spp. are not consumed as foods and possess no established nutritional profile in the conventional macronutrient or micronutrient sense. Phytochemically, stem bark of V. elongata is characterized by a high phenolic load (14.6% of hydroethanolic extract by weight), with flavonoids comprising approximately 50% of that fraction—including gallic acid, catechin, rutin, quinic acid, and C-glycosyl flavonoids. V. venosa bark and leaves yield phenolic acids (ferulic, gallic, p-coumaric) and flavonoids (quercetin, quercetrin, kaempferol, catechin), with ferulic acid as the quantitatively dominant antioxidant species. Sesquiterpenes (nerolidol) dominate the leaf essential oil of V. surinamensis, while the hallucinogenically active bark resin of V. theiodora and relatives is concentrated in indole tryptamine alkaloids (DMT, 5-MeO-DMT, bufotenine). Bioavailability of any compound class has not been studied in human or animal pharmacokinetic models; extraction solvent profoundly influences compound yield, with hydroethanolic solvents favoring polyphenols and dichloromethane favoring lipophilic polyketides.
How It Works
Mechanism of Action
The hallucinogenic activity of Virola resin is driven by tryptamine alkaloids—principally 5-MeO-DMT and DMT—which act as full agonists at serotonergic 5-HT2A receptors in the prefrontal cortex, producing glutamate release, disruption of default mode network activity, and the characteristic visionary state. Phenolic compounds such as gallic acid, catechin, and rutin exert gastroprotective and antioxidant effects via direct radical scavenging (hydroxyl and peroxyl quenching) and upregulation of endogenous mucosal defenses, while ferulic acid competitively inhibits α-glucosidase at the active site, slowing carbohydrate hydrolysis. The stilbene (Z)-3,5,4′-trihydroxystilbene suppresses cancer cell proliferation through mechanisms likely involving disruption of cell cycle progression analogous to—but far more potent than—resveratrol's known inhibition of cyclin-dependent kinases and induction of apoptosis, though direct molecular targets in Virola systems have not been confirmed by receptor-binding or genomic studies. Nerolidol from V. surinamensis essential oil disrupts Plasmodium parasite membrane integrity during the trophozoite stage, and neolignans from V. pavonis interfere with Leishmania donovani viability through as-yet-uncharacterized membrane or metabolic disruption at 100 µM.
Clinical Evidence
No clinical trials evaluating Virola spp. extracts, isolated compounds, or traditional preparations in human subjects have been identified in any available database. All quantified outcome data—IC₅₀ values for cytotoxicity, percentage inhibition of parasite stages, and α-glucosidase inhibitory activity—derive from cell-based or enzymatic assays conducted in vitro, with rodent antiulcer models representing the only in vivo preclinical evidence. Effect sizes from cell-line studies are notable (e.g., polyketide IC₅₀ 2–4 µg/mL in drug-resistant cancer cells; 100% Plasmodium schizont inhibition by nerolidol-rich oil), but the translation gap to human efficacy and safety is entirely unbridged. Confidence in any clinical benefit is therefore extremely low, and Virola spp. cannot be recommended for therapeutic use outside of carefully supervised ethnobotanical or investigational research contexts.
Safety & Interactions
The safety profile of Virola spp. in humans is essentially uncharacterized; no formal toxicology studies, maximum tolerated dose studies, or long-term safety assessments have been conducted, and in vitro cytotoxicity data (polyketide IC₅₀ 2–4 µg/mL against cancer cell lines) raises concern about potential non-selective cellular toxicity at higher concentrations. The tryptamine alkaloids in the hallucinogenic resin—particularly 5-MeO-DMT—carry significant risks including acute cardiovascular stimulation, serotonin syndrome (especially when combined with monoamine oxidase inhibitors, SSRIs, or SNRIs), psychological destabilization, and risk of vomiting and aspiration during insufflation ceremonies; these risks are not trivial and have resulted in adverse events in non-traditional settings. No drug interaction studies exist for Virola phytochemicals, but the presence of potent serotonergic alkaloids creates a plausible and serious interaction risk with any serotonergic psychiatric medication, and the α-glucosidase inhibitory activity of ferulic acid suggests theoretical additive hypoglycemic effects with antidiabetic drugs. Virola preparations are contraindicated in pregnancy and lactation given the presence of cytotoxic compounds and psychoactive alkaloids, and self-administration outside of rigorously supervised medical or indigenous ceremonial settings cannot be considered safe under any currently available evidence.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Virola spp.YakeeParicáEpenáNyakwanaVirola theiodoraVirola elongataVirola sebiferaVirola surinamensisVirola venosaVirola pavonis
Frequently Asked Questions
What is Nixi Pae and how is it used traditionally?
Nixi Pae is a hallucinogenic snuff prepared from the bark resin of Virola trees (family Myristicaceae) by Yanomami and upper Orinoco Amazonian tribes; it is insufflated nasally during shamanic ceremonies to induce visionary states and facilitate healing rituals. The resin is scraped from the inner bark, heated to concentrate alkaloids, dried, and often mixed with plant ash and Justicia pectoralis before being blown into the nostrils through a long tube by a ceremonial specialist.
What psychoactive compounds are in Virola resin?
Virola bark resin contains indole tryptamine alkaloids—principally N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), along with bufotenine in some species—which act as potent agonists at serotonin 5-HT2A receptors in the brain, producing the characteristic intense hallucinogenic effects. These are the same core psychoactive molecules found in ayahuasca brews, though Virola resin delivers them via nasal insufflation rather than oral ingestion.
Does Virola have anticancer properties?
Preclinical in vitro studies show notable anticancer activity: a stilbene compound, (Z)-3,5,4′-trihydroxystilbene, inhibits Caco-2 colon cancer cell growth by 70% at just 0.25 µM—approximately 100 times more potent than resveratrol—and polyketides from V. sebifera exhibit IC₅₀ values of 2–4 µg/mL against OVCAR03 ovarian and multidrug-resistant NCI-ADR cancer cell lines. However, no animal tumor studies or human clinical trials have been conducted, so these findings cannot be translated into cancer treatment claims at this time.
Is Nixi Pae or Virola extract safe to use?
No formal human safety or toxicology data exist for any Virola extract or preparation; the hallucinogenic resin contains 5-MeO-DMT and DMT, which pose serious risks of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors, and carry cardiovascular and psychological risks in unsupervised settings. In vitro cytotoxicity data additionally suggest potential non-selective cellular toxicity at higher concentrations, and Virola preparations are absolutely contraindicated in pregnancy given the presence of both potent psychoactive alkaloids and cytotoxic compounds.
Are there any clinical trials on Virola or Nixi Pae?
No human clinical trials on Virola species extracts, isolated compounds, or traditional Nixi Pae preparations have been identified in available literature or clinical trial registries as of the most recent evidence synthesis (2021 review). All published quantitative data—IC₅₀ values, percentage inhibition figures, and antiulcer effects—derive from cell-line assays, enzymatic inhibition assays, and rodent models, meaning the evidence base is preclinical and early-stage with very low confidence in human efficacy or safety.
What is the difference between Virola resin and Virola extract supplements?
Virola resin is the crude bark exudate traditionally used by indigenous peoples and contains the full spectrum of alkaloids and tryptamines in their natural ratios. Virola extract supplements are processed concentrations that may isolate specific compounds or standardize alkaloid content, potentially altering bioavailability and effects compared to the traditional resin form. The extraction method (solvent-based, water-based, or resin collection) significantly impacts which compounds are preserved and their relative potency.
Can Virola compounds interact with serotonergic medications like SSRIs or MAOIs?
Virola contains tryptamine alkaloids that interact with serotonin pathways, presenting a potential concern for concurrent use with SSRIs, SNRIs, and especially MAOIs due to the risk of serotonin syndrome. The alkaloid composition and bioavailability of Virola products vary widely, making interaction risk difficult to predict without standardized dosing data. Anyone taking psychiatric medications should consult a healthcare provider before using Virola products, as specific interaction studies in humans are not available.
Why might Virola's anticancer stilbenes and polyketides have different bioavailability than the alkaloid compounds?
Virola contains both tryptamine alkaloids (water and lipid-soluble) and phenolic compounds like stilbenes and polyketides, which have distinct molecular structures affecting how they are absorbed, metabolized, and distributed in the body. The anticancer stilbenes and polyketides may have lower oral bioavailability and are metabolized differently than the psychoactive alkaloids, potentially limiting their therapeutic efficacy when taken orally as supplements. Traditional resin preparation methods may not optimize extraction of the less abundant anticancer compounds, whereas targeted extraction or processing could theoretically enhance their bioavailability.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w nixi-pae-virola-spp curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
